Literature DB >> 11507064

Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells.

K P Bhat1, J M Pezzuto.   

Abstract

Trans-3,4',5-trihydroxystilbene (resveratrol), a polyphenolic compound found in the human diet, was reported recently to serve as an estrogen agonist with cultured MCF-7 cells transfected with estrogen response element-luciferase reporter plasmids. As currently shown, treatment of cultured human endometrial adenocarcinoma (Ishikawa) cells with resveratrol (concentrations as high as 10 microM) did not significantly increase the levels of an estrogen-inducible marker enzyme, alkaline phosphatase. To the contrary, when alkaline phosphatase was induced by treatment with 1 nM of 17beta-estradiol (E(2)), resveratrol exhibited a dose-dependent decrease in activity (IC(50) = 2.3 microM). Furthermore, when Ishikawa cells were treated with resveratrol as a single agent, estrogen-inducible progesterone receptor (PR) was not enhanced, and PR expression induced by treatment with E(2) was inhibited by resveratrol in a dose-dependent fashion at both the mRNA and protein levels. In addition, resveratrol mediated suppression of a functional activity of PR as demonstrated by down-regulation of alpha(1)-integrin expression induced by E(2) plus progesterone. With transient transfection experiments conducted with Ishikawa cells, antiestrogenic effects were confirmed by dose-dependent inhibition of E(2)-induced estrogen response element-luciferase transcriptional activity. Because resveratrol antagonized estrogenic effects in Ishikawa cells, competitive binding analyses were performed to examine the potential of displacing [(3)H]E(2) from human estrogen receptor (ER). Resveratrol showed no discernable activity with ER-alpha, but with ER-beta, E(2) was displaced with an IC(50) of 125 microM. However, mRNA and protein expression of ER-alpha but not ER-beta were suppressed by resveratrol in Ishikawa cells, in the concentration range of 5-15 microM. In addition, in the presence or absence of E(2), resveratrol inhibited Ishikawa cell proliferation in a time-dependent manner with cells accumulating in the S phase of the cycle < or =48 h. This effect was reversible. Analysis of some critical cell cycle proteins revealed a specific increase in expression of cyclins A and E but a decrease in cyclin-dependent kinase 2. These data suggest resveratrol exerts an antiproliferative effect in Ishikawa cells, and the effect may be mediated by both estrogen-dependent and -independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507064

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Resveratrol, an effective regulator of ovarian development and oocyte apoptosis.

Authors:  X-X Kong; Y-C Fu; J-J Xu; X-L Zhuang; Z-G Chen; L-L Luo
Journal:  J Endocrinol Invest       Date:  2011-07-07       Impact factor: 4.256

2.  Resveratrol and endometrium: a closer look at an active ingredient of red wine using in vivo and in vitro models.

Authors:  S C Amaya; R F Savaris; C J Filipovic; J D Wise; E Hestermann; S L Young; B A Lessey
Journal:  Reprod Sci       Date:  2014-03-06       Impact factor: 3.060

3.  Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells.

Authors:  Nicolas G Azios; Suranganie F Dharmawardhane
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

4.  Dose-dependency of resveratrol in providing health benefits.

Authors:  Subhendu Mukherjee; Jocelyn I Dudley; Dipak K Das
Journal:  Dose Response       Date:  2010-03-18       Impact factor: 2.658

Review 5.  Potential Therapeutic Targets of Resveratrol, a Plant Polyphenol, and Its Role in the Therapy of Various Types of Cancer.

Authors:  Saleh A Almatroodi; Mohammed A Alsahli; Abdullah S M Aljohani; Fahad A Alhumaydhi; Ali Yousif Babiker; Amjad Ali Khan; Arshad Husain Rahmani
Journal:  Molecules       Date:  2022-04-21       Impact factor: 4.927

6.  Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity.

Authors:  Iain A Murray; Jose L Morales; Colin A Flaveny; Brett C Dinatale; Chris Chiaro; Krishnegowda Gowdahalli; Shantu Amin; Gary H Perdew
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

7.  Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis.

Authors:  Udai P Singh; Narendra P Singh; Balwan Singh; Lorne J Hofseth; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2009-11-25       Impact factor: 4.030

Review 8.  A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer.

Authors:  Hajar Ku Yasin; Anthony H Taylor; Thangesweran Ayakannu
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

9.  The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Oncol       Date:  2011-12-07       Impact factor: 4.375

10.  Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells.

Authors:  Emilie Sexton; Céline Van Themsche; Kim LeBlanc; Sophie Parent; Pascal Lemoine; Eric Asselin
Journal:  Mol Cancer       Date:  2006-10-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.